Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Anne Floquet et al.|The Lancet Oncology|2021Cited by 412
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyKuniko Sunami, Takashi Kohno, Eisaku Furukawa et al.|Cancer Science|2019Cited by 375
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Yutaka Fujiwara et al.|Clinical Cancer Research|2021Cited by 97
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancerTakaaki Mizuno, Kenji Tamura|Oncology Letters|2020Cited by 21
HER3 protein expression as a risk factor for post‑operative recurrence in patients with early‑stage adenocarcinoma and adenosquamous carcinoma of the cervixTakaaki Mizuno, Kenji Tamura|Oncology Letters|2020Cited by 10